411 related articles for article (PubMed ID: 22869723)
1. Bodywide skipping of exons 45-55 in dystrophic mdx52 mice by systemic antisense delivery.
Aoki Y; Yokota T; Nagata T; Nakamura A; Tanihata J; Saito T; Duguez SM; Nagaraju K; Hoffman EP; Partridge T; Takeda S
Proc Natl Acad Sci U S A; 2012 Aug; 109(34):13763-8. PubMed ID: 22869723
[TBL] [Abstract][Full Text] [Related]
2. Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy.
Echigoya Y; Lim KRQ; Trieu N; Bao B; Miskew Nichols B; Vila MC; Novak JS; Hara Y; Lee J; Touznik A; Mamchaoui K; Aoki Y; Takeda S; Nagaraju K; Mouly V; Maruyama R; Duddy W; Yokota T
Mol Ther; 2017 Nov; 25(11):2561-2572. PubMed ID: 28865998
[TBL] [Abstract][Full Text] [Related]
3. Exon Skipping Therapy Using Phosphorodiamidate Morpholino Oligomers in the mdx52 Mouse Model of Duchenne Muscular Dystrophy.
Miyatake S; Mizobe Y; Takizawa H; Hara Y; Yokota T; Takeda S; Aoki Y
Methods Mol Biol; 2018; 1687():123-141. PubMed ID: 29067660
[TBL] [Abstract][Full Text] [Related]
4. Direct Reprogramming of Human DMD Fibroblasts into Myotubes for In Vitro Evaluation of Antisense-Mediated Exon Skipping and Exons 45-55 Skipping Accompanied by Rescue of Dystrophin Expression.
Lee JJA; Saito T; Duddy W; Takeda S; Yokota T
Methods Mol Biol; 2018; 1828():141-150. PubMed ID: 30171539
[TBL] [Abstract][Full Text] [Related]
5. In Vitro Multiexon Skipping by Antisense PMOs in Dystrophic Dog and Exon 7-Deleted DMD Patient.
Nakamura A; Aoki Y; Tsoumpra M; Yokota T; Takeda S
Methods Mol Biol; 2018; 1828():151-163. PubMed ID: 30171540
[TBL] [Abstract][Full Text] [Related]
6. [Exon skipping therapy for Duchenne muscular dystrophy by using antisense Morpholino].
Takeda S
Rinsho Shinkeigaku; 2009 Nov; 49(11):856-8. PubMed ID: 20030230
[TBL] [Abstract][Full Text] [Related]
7. In Vivo Evaluation of Single-Exon and Multiexon Skipping in mdx52 Mice.
Mizobe Y; Miyatake S; Takizawa H; Hara Y; Yokota T; Nakamura A; Takeda S; Aoki Y
Methods Mol Biol; 2018; 1828():275-292. PubMed ID: 30171548
[TBL] [Abstract][Full Text] [Related]
8. Skipping multiple exons of dystrophin transcripts using cocktail antisense oligonucleotides.
Echigoya Y; Yokota T
Nucleic Acid Ther; 2014 Feb; 24(1):57-68. PubMed ID: 24380394
[TBL] [Abstract][Full Text] [Related]
9. In-frame dystrophin following exon 51-skipping improves muscle pathology and function in the exon 52-deficient mdx mouse.
Aoki Y; Nakamura A; Yokota T; Saito T; Okazawa H; Nagata T; Takeda S
Mol Ther; 2010 Nov; 18(11):1995-2005. PubMed ID: 20823833
[TBL] [Abstract][Full Text] [Related]
10. In vitro evaluation of novel antisense oligonucleotides is predictive of in vivo exon skipping activity for Duchenne muscular dystrophy.
Wang Q; Yin H; Camelliti P; Betts C; Moulton H; Lee H; Saleh AF; Gait MJ; Wood MJ
J Gene Med; 2010 Apr; 12(4):354-64. PubMed ID: 20235089
[TBL] [Abstract][Full Text] [Related]
11. Antisense PMO cocktails effectively skip dystrophin exons 45-55 in myotubes transdifferentiated from DMD patient fibroblasts.
Lee J; Echigoya Y; Duddy W; Saito T; Aoki Y; Takeda S; Yokota T
PLoS One; 2018; 13(5):e0197084. PubMed ID: 29771942
[TBL] [Abstract][Full Text] [Related]
12. Antisense oligo-mediated multiple exon skipping in a dog model of duchenne muscular dystrophy.
Yokota T; Hoffman E; Takeda S
Methods Mol Biol; 2011; 709():299-312. PubMed ID: 21194037
[TBL] [Abstract][Full Text] [Related]
13. A
Echigoya Y; Trieu N; Duddy W; Moulton HM; Yin H; Partridge TA; Hoffman EP; Kornegay JN; Rohret FA; Rogers CS; Yokota T
Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884867
[TBL] [Abstract][Full Text] [Related]
14. Exons 45-55 Skipping Using Mutation-Tailored Cocktails of Antisense Morpholinos in the DMD Gene.
Echigoya Y; Lim KRQ; Melo D; Bao B; Trieu N; Mizobe Y; Maruyama R; Mamchaoui K; Tanihata J; Aoki Y; Takeda S; Mouly V; Duddy W; Yokota T
Mol Ther; 2019 Nov; 27(11):2005-2017. PubMed ID: 31416775
[TBL] [Abstract][Full Text] [Related]
15. Wild-type mouse models to screen antisense oligonucleotides for exon-skipping efficacy in Duchenne muscular dystrophy.
Cao L; Han G; Gu B; Yin H
PLoS One; 2014; 9(11):e111079. PubMed ID: 25365558
[TBL] [Abstract][Full Text] [Related]
16. Exons 45-55 Skipping Using Antisense Oligonucleotides in Immortalized Human DMD Muscle Cells.
He M; Yokota T
Methods Mol Biol; 2023; 2640():313-325. PubMed ID: 36995604
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Multi-exon Skipping Treatment in Duchenne Muscular Dystrophy Dog Model Neonates.
Lim KRQ; Echigoya Y; Nagata T; Kuraoka M; Kobayashi M; Aoki Y; Partridge T; Maruyama R; Takeda S; Yokota T
Mol Ther; 2019 Jan; 27(1):76-86. PubMed ID: 30448197
[TBL] [Abstract][Full Text] [Related]
18. Biochemical characterization of patients with in-frame or out-of-frame DMD deletions pertinent to exon 44 or 45 skipping.
Anthony K; Arechavala-Gomeza V; Ricotti V; Torelli S; Feng L; Janghra N; Tasca G; Guglieri M; Barresi R; Armaroli A; Ferlini A; Bushby K; Straub V; Ricci E; Sewry C; Morgan J; Muntoni F
JAMA Neurol; 2014 Jan; 71(1):32-40. PubMed ID: 24217213
[TBL] [Abstract][Full Text] [Related]
19. Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy.
Miskew Nichols B; Aoki Y; Kuraoka M; Lee JJ; Takeda S; Yokota T
J Vis Exp; 2016 May; (111):. PubMed ID: 27285612
[TBL] [Abstract][Full Text] [Related]
20. Dantrolene enhances antisense-mediated exon skipping in human and mouse models of Duchenne muscular dystrophy.
Kendall GC; Mokhonova EI; Moran M; Sejbuk NE; Wang DW; Silva O; Wang RT; Martinez L; Lu QL; Damoiseaux R; Spencer MJ; Nelson SF; Miceli MC
Sci Transl Med; 2012 Dec; 4(164):164ra160. PubMed ID: 23241744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
